Prognostic factor analysis of elderly patients with small-cell lung cancer
10.3760/cma.j.issn.0254-9026.2019.12.009
- VernacularTitle: 老年小细胞肺癌患者预后分析
- Author:
Yi YIN
1
;
Zhangzhou HUANG
;
Yunjian HUANG
;
Biao WU
;
Wu ZHUANG
Author Information
1. Department of Thoracic Medical Oncology, Fujian Cancer Hospital & Fujian Medical University Affiliated-Cancer Hospital, Fuzhou 350014, China
- Publication Type:Journal Article
- Keywords:
Smallcell lung carcinoma;
Prognosis
- From:
Chinese Journal of Geriatrics
2019;38(12):1357-1362
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To retrospectively analyze clinical data of elderly patients with small-cell lung cancer(SCLC)in order to investigate their prognostic factors.
Methods:Clinical data of SCLC patients aged 65 years and over in our hospital from January 2006 to February 2017 were analyzed.Survival data were analyzed by Kaplan-Meier method.Univariate analysis of prognosis was conducted by Log rank test.Multivariate analysis was performed by Cox regression.
Results:A total of 143 patients were enrolled, the median overall survival(OS)was 17.9 months, with 21.3 months for limit stage(LD)and 9.6 months for extensive stage(ED). For LD patients, age(HR=18.688, 95%CI: 3.237-107.889), smoking index(HR=2.783, 95%CI: 1.196-6.475), thoracic irradiation(HR=0.305, 95%CI: 0.120-0.779), chemotherapy efficacy(HR=0.210, 95%CI: 0.065-0.685)were the independent risk factors for the prognosis.For ED patients, chemotherapy cycles(HR=0.461, 95%CI: 0.229-0.927)and performance status(HR=0.422, 95%CI: 0.218-0.818)were the independent risk factors for prognosis.
Conclusions:Smoking index, tumor stage and treatment mode can influence the survival of SCLC patients.The LD patients, who were aged less than 75 years, with smoking index less than 1000, receiving thoracic irradiation and achieving remission with chemotherapy, show a longer OS.For ED patients, a good performance status and sufficient chemotherapy can predict an improved OS.
